Literature DB >> 20175194

Identification of chromosomal aberrations of metastatic potential in colorectal carcinoma.

Shogo Yamamoto1, Yutaka Midorikawa, Teppei Morikawa, Yoji Nishimura, Hirohiko Sakamoto, Shumpei Ishikawa, Kiwamu Akagi, Hiroyuki Aburatani.   

Abstract

In colorectal cancer (CRC) care, treatment decisions depend on the efforts to estimate the metastatic potential of tumors. The liver is one of the most common metastatic sites of CRC and the prognosis of CRC patients often reflects metastases to distant sites. To identify chromosomal aberrations associated with liver metastasis, we performed allelic copy number analysis for CRC with or without synchronous liver metastasis using genotyping arrays. By allelic copy number analysis of CRC samples, we observed common aberrations in 14 chromosomal arms in two groups, that is, gains on 7p22.3-p11.2, 8q22.3-q24.3, 13q12.12-q34, and 20q11.22-q13.33 and loss of heterozygosity (LOH) on 4q12-q35.1, 5q11.2-q35.3, 8p23.3-p12, 15q11.2-q26.3, 17p13.3-p11.2, 17q11.2-q25.1, 18p11.32-p11.21, 18q11.2-q23, 20p13-p12.1, and 22q11.1-q13.32. We found that gains on 20p13-p12.1 and 20q11.21-q13.33 and LOH on 6q14.1-q25.1 were more frequent in CRC with liver metastasis. We also compared chromosomal aberrations in primary CRC lesions with those of the corresponding liver metastasis and found that the allelic genome imbalance status of a metastatic lesion is similar to that of the primary cancer, which suggests that chromosomal aberrations are largely maintained on hematogenous spread. Intriguingly, several chromosomal aberrations in CRC were found in the primary cancer but not in the corresponding liver metastasis, thus suggesting heterogeneity of cancer cells within solid tumors or the presence of events uniquely developed in primary tumors. Consequently, CRC with and without liver metastasis harbor similar chromosomal aberrations, and chromosomal aberration at 6q, 20p, and 20q may be involved in the process of liver metastasis of CRC. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20175194     DOI: 10.1002/gcc.20759

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  14 in total

1.  Response to an exercise intervention after endometrial cancer: differences between obese and non-obese survivors.

Authors:  K Basen-Engquist; C Carmack; J Brown; A Jhingran; G Baum; J Song; S Scruggs; M C Swartz; M G Cox; K H Lu
Journal:  Gynecol Oncol       Date:  2014-04       Impact factor: 5.482

2.  Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma.

Authors:  Dong Wang; Zhong-Zheng Zhu; Hongmei Jiang; Jiayi Zhu; Wen-Ming Cong; Bing-Ji Wen; Song-Qin He; Shu-Fang Liu
Journal:  Hepatol Int       Date:  2015-06-12       Impact factor: 6.047

3.  A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression.

Authors:  C Chang; J Liu; W He; M Qu; X Huang; Y Deng; L Shen; X Zhao; H Guo; J Jiang; X Y Fu; R Huang; D Zhang; J Yan
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

4.  CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma.

Authors:  Guoan Chen; So Hee Kim; Amanda N King; Lili Zhao; Robert U Simpson; Paul J Christensen; Zhuwen Wang; Dafydd G Thomas; Thomas J Giordano; Lin Lin; Dean E Brenner; David G Beer; Nithya Ramnath
Journal:  Clin Cancer Res       Date:  2010-12-17       Impact factor: 12.531

5.  Deletion and down-regulation of HRH4 gene in gastric carcinomas: a potential correlation with tumor progression.

Authors:  Chao Zhang; Yi Xiong; Jiana Li; Yang Yang; Li Liu; Wen Wang; Luo Wang; Manhui Li; Zhengyu Fang
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

6.  Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.

Authors:  S Tsuji; Y Midorikawa; T Takahashi; K Yagi; T Takayama; K Yoshida; Y Sugiyama; H Aburatani
Journal:  Br J Cancer       Date:  2011-11-17       Impact factor: 7.640

7.  Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.

Authors:  Taiki Masuda; Toshiaki Ishikawa; Kaoru Mogushi; Satoshi Okazaki; Megumi Ishiguro; Satoru Iida; Hiroshi Mizushima; Hiroshi Tanaka; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Int J Oncol       Date:  2016-01-11       Impact factor: 5.650

8.  Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.

Authors:  Anita Sveen; Inger Marie Løes; Sharmini Alagaratnam; Gro Nilsen; Maren Høland; Ole Christian Lingjærde; Halfdan Sorbye; Kaja Christine Graue Berg; Arild Horn; Jon-Helge Angelsen; Stian Knappskog; Per Eystein Lønning; Ragnhild A Lothe
Journal:  PLoS Genet       Date:  2016-07-29       Impact factor: 5.917

9.  Reduced rate of copy number aberrations in mucinous colorectal carcinoma.

Authors:  Niek Hugen; Femke Simmer; Leonie J M Mekenkamp; Miriam Koopman; Evert van den Broek; Johannes H W de Wilt; Cornelis J A Punt; Bauke Ylstra; Gerrit A Meijer; Iris D Nagtegaal
Journal:  Oncotarget       Date:  2015-09-22

10.  Significant evidence of linkage for a gene predisposing to colorectal cancer and multiple primary cancers on 22q11.

Authors:  Craig Teerlink; Quentin Nelson; Randall Burt; Lisa Cannon-Albright
Journal:  Clin Transl Gastroenterol       Date:  2014-02-27       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.